Unnamed: 0,title,date,stock,sentiment
233874.0,77 Biggest Movers From Yesterday,2020-06-05 05:18:00-04:00,CGEN,neutral
233875.0,Stocks That Hit 52-Week Highs On Wednesday,2020-06-03 10:45:00-04:00,CGEN,neutral
233876.0,"Cramer Weighs In On Ciena, Harley-Davidson And More",2020-06-02 07:14:00-04:00,CGEN,neutral
233877.0,Compugen shares are trading higher after the company announced FDA Clearance of its IND application for Phase 1/2  Triple Combination Study Of COM701 With Bristol Myers Squibb's Opdivo And Tigit Inhibitor.,2020-06-01 07:39:00-04:00,CGEN,positive
233878.0,Compugen Announces FDA Clearance Of IND Application For Phase 1/2 Triple Combination Study Of COM701 With Bristol Myers Squibb's Opdivo (Nivolumab) And TIGIT Inhibitor,2020-06-01 07:11:00-04:00,CGEN,negative
233879.0,Compugen Announces FDA Approval of its Investigational New Drug Application for a Phase 1/2 Triple Combination Study of COM701 with Bristol Myers Squibb's Opdivo and TIGIT Inhibitor,2020-06-01 07:05:00-04:00,CGEN,positive
233880.0,72 Biggest Movers From Friday,2020-06-01 04:53:00-04:00,CGEN,neutral
233881.0,Compugen Doses First Patient In COM701 Phase 1 Monotherapy Expansion Cohort,2020-05-27 07:11:00-04:00,CGEN,neutral
233882.0,60 Biggest Movers From Yesterday,2020-05-15 04:53:00-04:00,CGEN,neutral
233883.0,42 Stocks Moving In Thursday's Mid-Day Session,2020-05-14 12:55:00-04:00,CGEN,neutral
233884.0,Shares of several healthcare companies are trading lower amid market weakness following US unemployment data and recent cautious comments from the WHO. Sentiment is also negative following cautious comments from Fed Chair Powell and bearish outlook from some major US investors on Wednesday. Negative investor sentiment has affected stocks across sectors for the session.,2020-05-14 11:18:00-04:00,CGEN,negative
233885.0,"Compugen shares are trading higher after Stifel initiated coverage on the company's stock with a Buy rating and $19 price target. UPDATE: Shares have since reversed, now lower.",2020-05-13 08:40:00-04:00,CGEN,positive
233886.0,"Stifel Initiates Coverage On Compugen with Buy Rating, Announces Price Target of $19",2020-05-13 06:04:00-04:00,CGEN,neutral
233887.0,Stocks That Hit 52-Week Highs On Monday,2020-05-11 10:28:00-04:00,CGEN,neutral
233888.0,Compugen shares are trading higher after SCB Leerink initiated coverage on the company's stock with an Outperform rating and announced a $15 price target.,2020-05-07 11:19:00-04:00,CGEN,positive
233889.0,Compugen Option Alert: May 15 $15 Calls Sweep (2) near the Ask: 1000 @ $0.646 vs 514 OI; Ref=$13.42,2020-05-07 10:18:00-04:00,CGEN,positive
233890.0,"Benzinga's Top Upgrades, Downgrades For May 7, 2020",2020-05-07 09:54:00-04:00,CGEN,positive
233891.0,"SVB Leerink Initiates Coverage On Compugen with Outperform Rating, Announces Price Target of $15",2020-05-07 06:54:00-04:00,CGEN,neutral
233892.0,Compugen shares are trading lower after the company reported Q1 earnings results.,2020-05-06 11:49:00-04:00,CGEN,neutral
233893.0,"Compugen Q1 EPS $(0.100), Inline",2020-05-06 07:14:00-04:00,CGEN,neutral
233894.0,Compugen to Present Updated Data From its Ongoing Phase 1 Trial of COM701 at 11:45am ET Today,2020-04-27 06:21:00-04:00,CGEN,neutral
233895.0,"The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight",2020-04-26 16:37:00-04:00,CGEN,negative
233896.0,Stocks That Hit 52-Week Highs On Wednesday,2020-04-22 10:20:00-04:00,CGEN,neutral
233897.0,"Benzinga's Top Upgrades, Downgrades For April 22, 2020",2020-04-22 09:40:00-04:00,CGEN,positive
233898.0,"Compugen shares are trading higher. The company reported a European patent for composition of COM701, backup antibodies for treatment of cancer. Roth Capital also initiated coverage on the stock with a Buy rating and $28 price target.",2020-04-22 08:50:00-04:00,CGEN,negative
233899.0,"Compugen Reports European Patent Office Granted Co. New Patent For Composition Of COM701, Backup Antibodies For Treatment Of Cancer",2020-04-22 08:23:00-04:00,CGEN,negative
233900.0,17 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-04-22 07:38:00-04:00,CGEN,neutral
233901.0,"Roth Capital Initiates Coverage On Compugen with Buy Rating, Announces Price Target to $28",2020-04-22 06:35:00-04:00,CGEN,neutral
233902.0,Stocks That Hit 52-Week Highs On Tuesday,2020-04-21 10:30:00-04:00,CGEN,neutral
233903.0,Compugen Announces Publication of a Peer Reviewed Paper on its Cancer Immunology Research,2020-04-20 07:05:00-04:00,CGEN,negative
233904.0,70 Biggest Movers From Yesterday,2020-04-17 04:53:00-04:00,CGEN,neutral
233905.0,52 Stocks Moving In Thursday's Mid-Day Session,2020-04-16 12:58:00-04:00,CGEN,neutral
233906.0,52 Stocks Moving In Thursday's Mid-Day Session,2020-04-16 12:57:00-04:00,CGEN,neutral
233907.0,Stocks That Hit 52-Week Highs On Thursday,2020-04-16 10:19:00-04:00,CGEN,neutral
233908.0,Compugen Announces First Patient Dosed in COM902 Phase 1 Trial for Patients With Advanced Malignancies,2020-04-06 07:08:00-04:00,CGEN,positive
233909.0,"SunTrust Robinson Humphrey Initiates Coverage On Compugen with Buy Rating, Announces $16 Price Target",2020-03-24 10:58:00-04:00,CGEN,neutral
233910.0,136 Biggest Movers From Yesterday,2020-03-13 05:20:00-04:00,CGEN,neutral
233911.0,Mid-Afternoon Market Update: Dow Tumbles Over 2000 Points; Inovio Pharmaceuticals Shares Gain,2020-03-12 14:54:00-04:00,CGEN,positive
233912.0,90 Stocks Moving In Thursday's Mid-Day Session,2020-03-12 12:21:00-04:00,CGEN,neutral
233913.0,34 Stocks Moving in Thursday's Pre-Market Session,2020-03-12 07:53:00-04:00,CGEN,neutral
233914.0,A Peek Into The Markets: US Stock Futures Down; Dow Futures Plunge Over 1100 Points,2020-03-12 06:24:00-04:00,CGEN,neutral
233915.0,Compugen Prices 8.3M Share Public Offering of Ordinary Shares @$9/Share,2020-03-12 06:06:00-04:00,CGEN,positive
233916.0,108 Biggest Movers From Yesterday,2020-03-11 05:34:00-04:00,CGEN,neutral
233917.0,82 Stocks Moving In Tuesday's Mid-Day Session,2020-03-10 12:25:00-04:00,CGEN,neutral
233918.0,Stocks That Hit 52-Week Highs On Tuesday,2020-03-10 10:19:00-04:00,CGEN,neutral
233919.0,123 Biggest Movers From Yesterday,2020-03-10 05:57:00-04:00,CGEN,neutral
233920.0,20 Healthcare Stocks Moving In Monday's Session,2020-03-09 13:40:00-04:00,CGEN,neutral
233921.0,101 Stocks Moving In Monday's Mid-Day Session,2020-03-09 12:00:00-04:00,CGEN,neutral
233922.0,52 Healthcare Stocks Moving In Monday's Pre-Market Session,2020-03-09 08:04:00-04:00,CGEN,neutral
233923.0,"Cantor Fitzgerald Reiterates Overweight on Compugen, Raises Price Target to $13",2020-02-21 06:23:00-05:00,CGEN,negative
233924.0,Stocks That Hit 52-Week Highs On Thursday,2020-02-20 10:26:00-05:00,CGEN,neutral
233925.0,Compugen Q4 EPS $(0.1) Beats $(0.11) Estimate,2020-02-20 08:36:00-05:00,CGEN,neutral
233926.0,Stocks That Hit 52-Week Highs On Wednesday,2020-02-19 10:32:00-05:00,CGEN,neutral
233927.0,Compugen Highlights Presentation Of Update On COM701 Phase 1 Trial At ASCO-SITC Symposium,2020-02-07 07:04:00-05:00,CGEN,neutral
233928.0,100 Biggest Movers From Yesterday,2020-02-07 04:30:00-05:00,CGEN,neutral
233929.0,74 Stocks Moving In Thursday's Mid-Day Session,2020-02-06 12:38:00-05:00,CGEN,neutral
233930.0,Stocks That Hit 52-Week Highs On Thursday,2020-02-06 10:39:00-05:00,CGEN,neutral
233931.0,Stocks That Hit 52-Week Highs On Wednesday,2020-02-05 10:16:00-05:00,CGEN,neutral
233932.0,Stocks That Hit 52-Week Highs On Tuesday,2020-02-04 10:18:00-05:00,CGEN,neutral
233933.0,Compugen Announces New US Patent For Methods Of Screening For Anti-PVRIG Antibodies,2020-02-04 07:07:00-05:00,CGEN,neutral
233934.0,Stocks That Hit 52-Week Highs On Monday,2020-02-03 11:44:00-05:00,CGEN,neutral
233935.0,Stocks That Hit 52-Week Highs On Wednesday,2020-01-29 10:16:00-05:00,CGEN,neutral
233936.0,Stocks That Hit 52-Week Highs On Tuesday,2020-01-28 11:05:00-05:00,CGEN,neutral
233937.0,Stocks That Hit 52-Week Highs On Monday,2020-01-27 10:33:00-05:00,CGEN,neutral
233938.0,Stocks That Hit 52-Week Highs On Friday,2020-01-24 10:41:00-05:00,CGEN,neutral
233939.0,"Cantor Fitzgerald Initiates Coverage On Compugen with Overweight Rating, Announces $10 Price Target",2020-01-16 06:46:00-05:00,CGEN,negative
233940.0,Stocks That Hit 52-Week Highs On Thursday,2020-01-09 15:15:00-05:00,CGEN,neutral
233941.0,Stocks That Hit 52-Week Highs On Friday,2019-12-27 11:27:00-05:00,CGEN,neutral
233942.0,"Compugen Q3 EPS $(0.1), Inline",2019-11-11 07:02:00-05:00,CGEN,neutral
233943.0,"Earnings Scheduled For November 11, 2019",2019-11-11 03:44:00-05:00,CGEN,neutral
233944.0,61 Biggest Movers From Yesterday,2019-11-06 04:19:00-05:00,CGEN,neutral
233945.0,Compugen Highlights Presentation Of Preclinical Data For COM902 Anti-TIGIT Program At SITC,2019-11-05 08:17:00-05:00,CGEN,neutral
233946.0,Compugen Presents Initial Data From Ongoing Phase 1 Trial Of COM701 In Patients With Advanced Solid Tumors At SITC,2019-11-05 08:17:00-05:00,CGEN,positive
233947.0,A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street,2019-11-04 07:29:00-05:00,CGEN,neutral
233948.0,Compugen Announces FDA Clearance of its Investigational New Drug Application for COM902,2019-11-04 07:08:00-05:00,CGEN,neutral
233949.0,70 Biggest Movers From Yesterday,2019-08-30 04:05:00-04:00,CGEN,neutral
233950.0,28 Healthcare Stocks Moving In Today's Pre-Market Session,2019-08-06 08:55:00-04:00,CGEN,neutral
233951.0,Compugen Files for $200M Mixed Shelf Offering,2019-08-05 07:39:00-04:00,CGEN,neutral
233952.0,Compugen Q2 EPS $(0.1) Beats $(0.14) Estimate,2019-08-05 07:05:00-04:00,CGEN,neutral
233953.0,Compugen Presents an Update on COM701 Phase 1 Trial at the 2019 ASCO Annual Meeting,2019-06-03 07:22:00-04:00,CGEN,neutral
233954.0,The Week Ahead In Biotech: ASCO Presentations In The Spotlight,2019-05-26 17:03:00-04:00,CGEN,neutral
233955.0,Compugen Q1 EPS $(0.14) Beats $(0.17) Estimate,2019-05-20 07:05:00-04:00,CGEN,neutral
233956.0,Compugen Reports Dosing Of First Patient In COM701/Opdivo Combo Arm Of Phase 1 Study In Patients With Advanced Solid Tumors,2019-05-20 07:04:00-04:00,CGEN,positive
233957.0,"Earnings Scheduled For May 20, 2019",2019-05-20 04:11:00-04:00,CGEN,neutral
233958.0,64 Biggest Movers From Yesterday,2019-04-18 05:17:00-04:00,CGEN,neutral
233959.0,42 Stocks Moving In Wednesday's Mid-Day Session,2019-04-17 12:35:00-04:00,CGEN,neutral
233960.0,44 Biggest Movers From Yesterday,2019-04-16 05:44:00-04:00,CGEN,neutral
233961.0,Compugen Highlights Presentation Of Update On COM701 Phase 1 Trial At 2019 AACR Annual Meeting,2019-04-03 07:02:00-04:00,CGEN,neutral
233962.0,"Compugen Highlights Its Entire Board, Members Of Mgmt. Purchased Shares During Mar. 2019; Details Of Purchases Not Disclosed",2019-03-26 07:10:00-04:00,CGEN,positive
233963.0,Compugen Announces Issuance Of Two US Composition Of Matter Patents For Its COM701 Immuno-Oncology Product Candidate,2019-03-12 07:50:00-04:00,CGEN,neutral
233964.0,Compugen Highlights Presentation Of Update On COM701 Phase 1 Trial At ASCO-SITC Symposium,2019-03-01 07:16:00-05:00,CGEN,neutral
233965.0,72 Biggest Movers From Yesterday,2019-02-27 04:55:00-05:00,CGEN,neutral
233966.0,54 Stocks Moving In Tuesday's Mid-Day Session,2019-02-26 12:18:00-05:00,CGEN,neutral
233967.0,Compugen Earlier Announced Corporate Restructuring,2019-02-26 09:36:00-05:00,CGEN,neutral
233968.0,Compugen Earlier Reported Q4 EPS $(0.16) Beats $(0.19) Estimate,2019-02-26 09:35:00-05:00,CGEN,neutral
233969.0,25 Stocks Moving In Tuesday's Pre-Market Session,2019-02-26 08:30:00-05:00,CGEN,neutral
233970.0,55 Biggest Movers From Yesterday,2019-01-23 05:19:00-05:00,CGEN,neutral
233971.0,Compugen Reports Its Phase 1 Trial Of COM701 Will Be Featured As Trial-In-Progress At ASCO-SITC Immuno-Oncology Symposium,2019-01-14 07:18:00-05:00,CGEN,neutral
233972.0,"Compugen Announces Issuance Of U.S. Patent For Com902, Its Tigit Antibody Product Candidate For Cancer Immunotherapy",2018-11-13 07:09:00-05:00,CGEN,negative
233973.0,88 Biggest Movers From Yesterday,2018-11-08 04:54:00-05:00,CGEN,neutral
233974.0,"Compugen Ltd. Q3 EPS $(0.05) Beats $(0.15) Estimate, Sales $7.8M Beat $2.6M Estimate",2018-11-07 08:26:00-05:00,CGEN,neutral
233975.0,"Don't Fixate On Market Woes, Just Make Your Trades",2018-10-12 15:09:00-04:00,CGEN,negative
233976.0,26 Stocks Moving In Thursday's Pre-Market Session,2018-10-11 09:10:00-04:00,CGEN,neutral
233977.0,Compugen Shares are trading higher after the announcement of a $12M investment and collaboration with Bristol-Myers Squibb.,2018-10-11 07:37:00-04:00,CGEN,positive
233978.0,"Bristol-Myers Squibb Reports Collaboration With Compugen To Evaluate Therapeutic Regimen In Advanced Solid Tumors, Will Make $12M Investment",2018-10-11 07:00:00-04:00,CGEN,positive
233979.0,40 Stocks Moving In Thursday's Mid-Day Session,2018-09-20 12:31:00-04:00,CGEN,neutral
233980.0,30 Stocks Moving In Thursday's Pre-Market Session,2018-09-20 08:15:00-04:00,CGEN,neutral
233981.0,Compugen Reports Milestone Payment In Cancer Immunotherapy Collaboration With Bayer; Co. Entitled Milestone Payment Of $7.8M At First Patient Dosing,2018-09-20 07:09:00-04:00,CGEN,negative
233982.0,Compugen Reports First Patient Dosed With COM701 As Treatment For First-In-Class Cancer Immunotherapy Antibody,2018-09-07 07:00:00-04:00,CGEN,negative
233983.0,"Compugen Q2 EPS $(0.19), Inline",2018-08-01 07:01:00-04:00,CGEN,neutral
233984.0,44 Biggest Movers From Yesterday,2018-07-03 05:54:00-04:00,CGEN,neutral
233985.0,38 Stocks Moving In Monday's Mid-Day Session,2018-07-02 12:29:00-04:00,CGEN,neutral
233986.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Mon., Jul. 2, 2018",2018-07-02 10:44:00-04:00,CGEN,positive
233987.0,Compugen Shares Jump 6.1 % After FDA Approves 2 Investigational New Drug Applications,2018-07-02 10:03:00-04:00,CGEN,positive
233988.0,Benzinga Pro's 5 Stocks To Watch Today,2018-07-02 09:10:00-04:00,CGEN,neutral
233989.0,28 Stocks Moving In Monday's Pre-Market Session,2018-07-02 08:06:00-04:00,CGEN,neutral
233990.0,Compugen and Bayer's Second Investigational New Drug Application for BAY 1905254 is Cleared by the FDA,2018-07-02 07:14:00-04:00,CGEN,positive
233991.0,A Peek Into The Markets: US Stock Futures Point To A Lower Wall Street Open,2018-07-02 07:08:00-04:00,CGEN,negative
233992.0,Compugen Announces FDA Clearance of its Investigational New Drug Application for COM701,2018-07-02 07:01:00-04:00,CGEN,neutral
233993.0,Compugen Reports 5.3M Share Offering At $3.95/Share,2018-06-15 07:00:00-04:00,CGEN,positive
233994.0,"Compugen Q1 EPS $0.00 vs $(0.17) In Same Qtr. Last Year, Sales $10M Beat $250K Estimate",2018-05-09 07:27:00-04:00,CGEN,neutral
233995.0,"UPDATE: Compugen Says FDA Informed It IND App Review Can Be Completed, Can Be Taken Off Clinical Hold Once Requested Info Is Provided By Co.",2018-04-27 07:26:00-04:00,CGEN,neutral
233996.0,Compugen Offers Update On Status Of INDA For COM701: FDA Requested Co. Provided Added CMC Info In Support Of Application,2018-04-27 07:25:00-04:00,CGEN,positive
233997.0,"Compugen Says Preclinical Data Presented by Bayer High the Efficacy of BAY 1905254, Formerly CGEN-15001T",2018-04-17 07:08:00-04:00,CGEN,neutral
233998.0,17 Stocks Moving In Tuesday's Pre-Market Session,2018-04-03 08:02:00-04:00,CGEN,neutral
233999.0,"Benzinga Pro's Most-Searched Tickers For Mon., Apr. 2, 2018",2018-04-02 11:40:00-04:00,CGEN,neutral
234000.0,Benzinga Pro's 5 Stocks To Watch Today,2018-04-02 10:04:00-04:00,CGEN,neutral
234001.0,28 Stocks Moving In Monday's Pre-Market Session,2018-04-02 08:00:00-04:00,CGEN,neutral
234002.0,Compugen to Receive a $10M Upfront Payment From AstraZeneca for MedImmune,2018-04-02 07:17:00-04:00,CGEN,neutral
234003.0,41 Biggest Movers From Thursday,2018-04-02 05:21:00-04:00,CGEN,neutral
234004.0,36 Stocks Moving In Thursday's Mid-Day Session,2018-03-29 12:21:00-04:00,CGEN,neutral
234005.0,"Benzinga's Top Upgrades, Downgrades For March 29, 2018",2018-03-29 09:41:00-04:00,CGEN,positive
234006.0,"Oppenheimer Initiates Coverage On Compugen Ltd. - Ordinary Shares with Outperform Rating, Announces $9.00 Price Target",2018-03-29 07:54:00-04:00,CGEN,positive
234007.0,31 Stocks Moving In Monday's Mid-Day Session,2018-03-26 12:37:00-04:00,CGEN,neutral
234008.0,38 Biggest Movers From Yesterday,2018-02-27 04:58:00-05:00,CGEN,neutral
234009.0,Compugen Reports Q4 EPS $(0.18) vs $(0.17) In Prior Year Period,2018-02-21 07:10:00-05:00,CGEN,neutral
234010.0,Mid-Afternoon Market Update: Shutterfly Surges On Earnings Beat; Forterra Shares Slide,2018-01-31 14:31:00-05:00,CGEN,positive
234011.0,28 Stocks Moving In Tuesday's Pre-Market Session,2018-01-30 08:00:00-05:00,CGEN,neutral
234012.0,38 Biggest Movers From Yesterday,2018-01-19 04:30:00-05:00,CGEN,neutral
234013.0,Compugen Q3 EPS $(0.19) vs $(0.19) Est.,2017-11-07 08:06:00-05:00,CGEN,neutral
234014.0,UPDATE: Compugen Says 'Bayer to provide process development and manufacturing services for COM902',2017-11-06 07:11:00-05:00,CGEN,neutral
234015.0,UPDATE: Compugen Says 'COM902 IND anticipated in 2019 to allow clinical testing of combination therapies with COM701',2017-11-06 07:11:00-05:00,CGEN,positive
234016.0,Compugen Reports Will Initiate Manufacturing Of COM902,2017-11-06 07:11:00-05:00,CGEN,neutral
234017.0,Compugen Enters Research Collaboration With Mount Sinai On Myeloid Immuno-Oncology Targets,2017-11-02 09:27:00-04:00,CGEN,neutral
234018.0,15 Biggest Mid-Day Gainers For Monday,2017-10-09 12:29:00-04:00,CGEN,neutral
234019.0,28 Stocks Moving In Monday's Pre-Market Session,2017-10-09 08:08:00-04:00,CGEN,neutral
234020.0,Mid-Day Market Update: La-Z-Boy Drops After Q1 Miss; Paratek Pharmaceuticals Shares Rise,2017-08-23 12:09:00-04:00,CGEN,positive
234021.0,Mid-Morning Market Update: Markets Open Lower; Lowe's Earnings Miss Expectations,2017-08-23 10:14:00-04:00,CGEN,negative
234022.0,"Compugen Q2 EPS $(0.18) vs $(0.18) Est., No Sales",2017-08-02 07:21:00-04:00,CGEN,negative
234023.0,Compugen Announces Paul Sekhri Chairman of the Board,2017-08-02 07:21:00-04:00,CGEN,neutral
234024.0,18 Biggest Mid-Day Losers For Wednesday,2017-07-26 13:04:00-04:00,CGEN,negative
234025.0,"Compugen Shares Down 10% Pre-Market Following Update For Collab Efforts With Bayer In Immuno-Oncology, Says Partnership Will Continue Based On CGEN-15001T",2017-07-26 09:20:00-04:00,CGEN,positive
234026.0,20 Stocks Moving In Wednesday's Pre-Market Session,2017-07-26 08:15:00-04:00,CGEN,neutral
234027.0,Compugen Offers Update For Collab Efforts With Bayer In Immuno-Oncology: Current Deal Will Continue Based On CGEN-15001T; Parties Are In Talks Related To Added Compugen Targets,2017-07-26 07:25:00-04:00,CGEN,positive
234028.0,25 Stocks Moving In Tuesday's Pre-Market Session,2017-07-25 08:24:00-04:00,CGEN,neutral
234029.0,"Compugen Issued Patent for COM701, its Lead Immuno-Oncology Product Candidate",2017-07-25 07:14:00-04:00,CGEN,neutral
234030.0,Mid-Morning Market Update: Markets Mostly Lower; Halliburton Profit Tops Estimates,2017-07-24 10:13:00-04:00,CGEN,positive
234031.0,Compugen Expecting Several Months of Delay to Submit IND for COM701,2017-05-31 07:02:00-04:00,CGEN,negative
234032.0,Compugen Reports Q1 EPS $(0.17) vs $(0.18) Est.,2017-05-09 07:14:00-04:00,CGEN,neutral
234033.0,Compugen Announces Lead Therapeutic Candidate COM902 Immuno-Oncology Program,2017-03-28 07:16:00-04:00,CGEN,neutral
234034.0,"Compugen Q4 EPS $(0.17) vs $(0.17) Est, Revenue $53K vs $150K Est",2017-02-15 07:21:00-05:00,CGEN,neutral
234035.0,Compugen Discloses its Cancer Immunotherapy Program Targeting TIGIT Immune Checkpoint,2016-12-07 07:25:00-05:00,CGEN,negative
234036.0,"Compugen Q3 EPS $(0.15) vs $(0.14) Est, Revenue $70K vs $460K Est",2016-11-07 07:10:00-05:00,CGEN,neutral
234037.0,Compugen Names Lead Therapeutic Candidate For CGEN-15029 Immuno-Oncology Program IND filing For COM701 Anticipated in 2017,2016-06-22 10:00:00-04:00,CGEN,neutral
234038.0,Compugen Announces CGEN-15029 as Lead Therapeutic Candidate,2016-06-22 07:10:00-04:00,CGEN,neutral
234039.0,"Compugen Reports Q1 EPS $(0.17) vs $(0.15) Est., Sales $100K vs $640K Est.",2016-05-10 07:05:00-04:00,CGEN,neutral
234040.0,Compugen Achieves Milestone Event With Bayer,2016-04-18 14:10:00-04:00,CGEN,neutral
234041.0,Compugen Achieves Preclinical Milestone In Partnership With Bayer,2016-04-18 07:15:00-04:00,CGEN,neutral
234042.0,Compugen Achieves Preclinical Milestone in Cancer Immunotherapy Collaboration with Bayer,2016-04-18 07:12:00-04:00,CGEN,negative
234043.0,Compugen Offers Results for CGEN-15029 Immuno-Oncology Therapeutic Program: Multiple blocking antibodies discovered for Compugen novel immune checkpoint target candidate for treatment of cancer,2016-02-29 07:14:00-05:00,CGEN,negative
234044.0,"Compugen Reports Q4 EPS ($0.01) vs. Est. ($0.11), Rev. $8.3M vs. Est. $3.33M",2016-02-09 07:10:00-05:00,CGEN,neutral
234045.0,"UPDATE: Further Details On Bayer, Compugen Deal In Terms Of Additional Milestones & Royalties",2015-12-11 08:38:00-05:00,CGEN,neutral
234046.0,"UPDATE: Compugen Says Received Upfront Payment of $10M, Added $15M of Joint Preclinical Milestone Payments for CGEN-1500IT, Eligible for Added $15M in Milestone Payments",2015-12-11 08:37:00-05:00,CGEN,neutral
234047.0,"UPDATE: Compugen Says Milestone Payment Relates to CGEN-1500IT Program, Will Receive $7.8M",2015-12-11 08:36:00-05:00,CGEN,neutral
234048.0,"6-K from Compugen Shows Co. Achieved Third Preclinical Milestone Payment Related to Cancer Immunotherapy Collab, License Deal with Bayer",2015-12-11 08:36:00-05:00,CGEN,negative
234049.0,Compugen Shares Halted News Pending,2015-12-11 08:28:00-05:00,CGEN,positive
234050.0,"Compugen Reports Q3 Loss of $0.13/Share vs Loss of $0.15/Share Est., Sales $200K vs $1.15M Est.",2015-11-03 07:08:00-05:00,CGEN,negative
234051.0,Compugen Discloses Antibody Drug Conjugate Program Results at the World ADC Summit in San Diego,2015-10-19 07:04:00-04:00,CGEN,neutral
234052.0,"FBR Capital Initiates Coverage on Compugen at Outperform, Announces $14.00 PT",2015-10-15 07:56:00-04:00,CGEN,neutral
234053.0,Compugen Discloses New Results Supporting CGEN-15052 as Novel Immune Checkpoint Target Candidate for Treatment of Cancer,2015-09-16 07:00:00-04:00,CGEN,positive
234054.0,Compugen Reports Q2 EPS $(0.14) vs. Est. $(0.13),2015-08-04 07:02:00-04:00,CGEN,neutral
234055.0,Benzinga's Top #PreMarket Losers,2015-06-24 08:23:00-04:00,CGEN,negative
234056.0,"Jefferies Assumes Compugen at Buy, Announces $11.00 PT",2015-04-23 10:53:00-04:00,CGEN,neutral
234057.0,Oppenheimer Is Excited About These 3 Biotech Stocks,2015-04-21 08:32:00-04:00,CGEN,positive
234058.0,"Oppenheimer Initiates Coverage on Compugen at Outperform, Announces $11.00 PT",2015-04-20 16:51:00-04:00,CGEN,neutral
234059.0,"Compugen Obtains Rights to Use Biological Systems, Materials from NIH",2015-04-14 07:09:00-04:00,CGEN,neutral
234060.0,Morning Market Gainers,2015-02-10 09:49:00-05:00,CGEN,neutral
234061.0,"Morning-Market Movers Led By Aeropostale, Coca-Cola & Coupons.Com",2015-02-10 09:34:00-05:00,CGEN,neutral
234062.0,"6-K from Compugen Reports Q4 Loss of $0.03/Share vs Loss of $0.11/Share Est., Sales $6.6M",2015-02-10 07:06:00-05:00,CGEN,negative
234063.0,Morning Market Gainers,2015-02-09 09:48:00-05:00,CGEN,neutral
234064.0,"Monday Morning Movers: Achillion Up, Regulus Down Following Drug Results",2015-02-09 09:05:00-05:00,CGEN,neutral
234065.0,Benzinga's Top #PreMarket Gainers,2015-02-09 08:07:00-05:00,CGEN,positive
234066.0,Compugen Announces Immuno-Oncology Research Collaboration with Johns Hopkins University,2014-12-18 07:04:00-05:00,CGEN,neutral
234067.0,Compugen Announces Experimental Confirmation of Additional Methodology for Discovery of Cancer-Related Immune Checkpoints,2014-12-02 07:13:00-05:00,CGEN,positive
234068.0,Stocks Hitting 52-Week Lows,2014-11-11 10:18:00-05:00,CGEN,negative
234069.0,"Compugen Ltd. Reports Q3 EPS of $(0.11), Inline; Revenue of $1.70M vs $1.90M Est",2014-10-29 07:09:00-04:00,CGEN,neutral
234070.0, Compugen Discloses Successful Validation Results For Novel B7/CD28–like Cancer Immunotherapy Target Candidate,2014-10-27 07:06:00-04:00,CGEN,positive
234071.0,Compugen Achieves Second Preclinical Milestone in Cancer Immunotherapy Collaboration with Bayer ,2014-10-14 14:02:00-04:00,CGEN,negative
234072.0,Morning Market Movers ,2014-10-01 09:39:00-04:00,CGEN,neutral
234073.0,US Stock Futures Edge Lower Ahead Of ADP Report,2014-10-01 07:38:00-04:00,CGEN,negative
234074.0,Compugen Reports Results Further Confirming CGEN-15049 as 'Promising' Target Candidate for Cancer Immunotherapy,2014-10-01 07:10:00-04:00,CGEN,negative
234075.0,F-3 from Compugen Shows Registration for $200M Mixed Securities Shelf,2014-08-26 16:08:00-04:00,CGEN,positive
234076.0,Compugen Names Ari Krashin CFO ,2014-08-25 07:03:00-04:00,CGEN,neutral
234077.0,Compugen Ltd. Reports Q2 EPS of $(0.05) vs $(0.11) Est,2014-08-06 07:12:00-04:00,CGEN,neutral
234078.0,Benzinga's Top #PreMarket Losers,2014-07-08 08:09:00-04:00,CGEN,negative
234079.0,Compugen Announces That it Will Receive $1.2M of Possible $30M Milestone Payment From Bayer Collaboration,2014-07-07 07:07:00-04:00,CGEN,neutral
234080.0,Benzinga's Top Initiations,2014-06-18 09:16:00-04:00,CGEN,positive
234081.0,"JMP Securities Initiates Coverage on Compugen Ltd. at Market Outperform, Announces $14.00 PT",2014-06-18 06:36:00-04:00,CGEN,positive
234082.0,Morning Market Movers ,2014-06-16 09:40:00-04:00,CGEN,neutral
234083.0,US Stock Futures Decline Ahead Of Economic Data,2014-06-16 07:32:00-04:00,CGEN,neutral
234084.0,Compugen Reports Positive Experimental Results for Novel Checkpoint Candidate CGEN-15052,2014-06-16 07:05:00-04:00,CGEN,positive
234085.0,Compugen Ltd. Reports Q1 EPS of $(0.04) vs $(0.10) Est; Revenue of $2.13M vs $1.84M Est,2014-05-19 07:01:00-04:00,CGEN,neutral
234086.0,"Earnings Scheduled For May 19, 2014",2014-05-19 05:30:00-04:00,CGEN,neutral
234087.0,Compugen Annpoints Avihai Shen CFO,2014-05-12 07:02:00-04:00,CGEN,neutral
234088.0,Compugen Issues Statement Related to Allegations of Insider Trading: Says Co. Itself Will Not Be Subject to Investigation,2014-04-07 09:05:00-04:00,CGEN,neutral
234089.0,Morning Market Movers ,2014-03-19 09:36:00-04:00,CGEN,neutral
234090.0,Benzinga's Top #PreMarket Gainers,2014-03-19 08:07:00-04:00,CGEN,positive
234091.0,"Jefferies Initiates Coverage on Compugen Ltd. at Buy, Announces $17.00 PT",2014-03-19 07:43:00-04:00,CGEN,neutral
234092.0,"Mornings Movers for Feb. 28, 2014: CETV, OTVI, MELI, REGI, GALE Moving Higher, ELGX, DECK, MDVN, CGEN, ARNA Lowr",2014-02-28 10:40:00-05:00,CGEN,neutral
234093.0,Compugen Ltd. Prices 6M Share Public Offering at $10.50 per Share,2014-02-28 09:17:00-05:00,CGEN,positive
234094.0,Benzinga's Top #PreMarket Losers,2014-02-28 08:15:00-05:00,CGEN,negative
234095.0,Compugen Announces Offering of Ordinary Shares,2014-02-27 16:17:00-05:00,CGEN,positive
234096.0,"McNicoll Lewis Vlak Initiates Coverage on Compugen Ltd. at Buy, Announces $14.00 PT",2014-02-06 17:03:00-05:00,CGEN,neutral
234097.0,Compugen to Significantly Expand Immuno-Oncology Activitiesin 2014 ,2014-01-07 09:28:00-05:00,CGEN,positive
234098.0,"Market Wrap For Monday, August 5: Stocks Close Mixed; Nasdaq Rises, Dow And S&P Fall Modestly",2013-08-05 16:38:00-04:00,CGEN,neutral
234099.0,Morning Market Movers ,2013-08-05 10:01:00-04:00,CGEN,neutral
234100.0,"Compugen Shares Rocket Higher as Co. Announces Collaboration, License Deal with Bayer for Antibody-Based Cancer Immunotherapies",2013-08-05 09:21:00-04:00,CGEN,negative
234101.0,Compugen Announces US Patent Allowance for Drug Candidate Recently Presented at 2013 American Thoracic Society Meeting ,2013-07-15 07:06:00-04:00,CGEN,neutral
234102.0,Compugen Files $100M Mixed Securities Shelf,2013-01-07 16:21:00-05:00,CGEN,positive
234103.0,Compugen Announces Discovery of Two Novel Immune Checkpoint Targets for   Cancer Immunotherapy,2012-10-31 08:24:00-04:00,CGEN,negative
234104.0,Compugen Drug Candidate Demonstrates Attenuation of Autoimmunity and Reestablishment of Immune Balance ,2012-09-10 07:05:00-04:00,CGEN,positive
234105.0,"UPDATE: Goldman Sachs Upgrades Qiagen NV to Neutral on M&A Outlook, HPV Visibility  ",2012-07-02 11:29:00-04:00,CGEN,neutral
234106.0,Compugen and Merck Serono Ventures to Jointly Establish New Biomarker Company Neviah Genomics Ltd.   ,2012-06-25 07:04:00-04:00,CGEN,neutral
234107.0,"Financial Breakfast: Morning News Summary for April 24, 2012",2012-04-24 07:41:00-04:00,CGEN,neutral
234108.0,A Peek Into The Market Before The Trading Starts,2012-04-24 07:22:00-04:00,CGEN,neutral
234109.0,Compugen Announces Initial Validation Results for Two Novel Immunomodulatory Proteins and Further Results for CGEN-15001   ,2012-04-24 07:08:00-04:00,CGEN,positive
234110.0,Compugen Says Cancer Target Results Demonstrate Significant Potential for Cancer Immunotherapy  ,2012-02-02 06:42:00-05:00,CGEN,negative
234111.0,Compugen and DiscoveRx Form Collaboration to Commercialize Novel Peptide Ligands for GPCR Drug Targets  ,2011-11-29 07:01:00-05:00,CGEN,positive
234112.0,Compugen Announces Initial Validation of Additional B7/CD28 Protein Family Based Product Candidate  ,2011-06-21 08:15:00-04:00,CGEN,neutral
234113.0,Compugen Announces Initial Validation of Additional B7/CD28 Protein Family Based Product Candidate ,2011-06-21 08:07:00-04:00,CGEN,neutral
234114.0,Compugen Discloses Discovery Method For Drug Candidates -Bloomberg,2011-05-19 07:20:00-04:00,CGEN,neutral
234115.0,Compugen Discloses Discovery Method for Drug Candidates That Interfere With Protein Conformations ,2011-05-19 07:04:00-04:00,CGEN,neutral
234116.0,Compugen Reports EPS of (0.06) vs. $(0.07) (CGEN),2011-05-11 07:49:00-04:00,CGEN,neutral
234117.0,Compugen Up 9.8% After Hitting 52-Week High (CGEN),2011-01-14 14:33:00-05:00,CGEN,neutral
234118.0,"Best Biotech Stocks To Own Now (CRIS, CGEN, SPPI, IPXL)",2011-01-13 10:27:00-05:00,CGEN,positive
234119.0,5 Bargain Biotech Stocks,2011-01-11 11:11:00-05:00,CGEN,positive
234120.0,A Peek Into The Market Before The Trading Starts,2010-12-30 07:46:00-05:00,CGEN,neutral
234121.0,Compugen Signs $5 Million R&D Funding Agreement   ,2010-12-30 07:28:00-05:00,CGEN,positive
234122.0,A Peek Into The Market Before The Trading Starts,2010-12-14 08:09:00-05:00,CGEN,neutral
234123.0,Compugen Announces Positive Therapeutic Effect of CGEN-15001 (CGEN),2010-12-14 07:44:00-05:00,CGEN,positive
234124.0,Compugen Ltd. Raises $19 Million Through Share Sale,2009-12-31 10:32:00-05:00,CGEN,positive
234125.0,"New 52-Week High Stocks (FSII, CGEN, MRM, CRIS)",2009-12-28 09:49:00-05:00,CGEN,neutral
234126.0,Compugen Ltd. (USA) (NASDAQ: CGEN) Climbs after Drug Discovery,2009-12-28 09:42:00-05:00,CGEN,neutral
234127.0,"Benzinga’s News Roundup (CALM, CGEN, VICL, TOBC, TEG, ACTU)",2009-12-28 09:05:00-05:00,CGEN,neutral
234128.0,"Benzinga’s Top Pre- Market Gainers (SVA, AMCS, FTK, CGEN, PAR, NVMI, CBY)",2009-12-28 08:18:00-05:00,CGEN,positive
234129.0,"Pfizer Deal Enhances Compugen Share Price, (CGEN, PFE, ATHX)",2009-12-23 12:32:00-05:00,CGEN,positive
234130.0,"Benzinga’s Top Gainers (CGEN, THC, FSII, ACHN, VG) ",2009-12-23 11:27:00-05:00,CGEN,positive
